PPD and ProtonMedia Win 2011 Microsoft Life Sciences Innovation Award

22 Jun. 2011


WILMINGTON, N.C., (June 22, 2011) - PPD, Inc. (Nasdaq: PPDI) today announced that Microsoft Corp. has named PPD and ProtonMedia winners of a Microsoft 2011 Life Sciences Innovation Award, recognizing their innovative use of ProtonMedia's ProtoSphere in creating PPD 3D. The virtual, collaborative environment improves the cost-effectiveness, speed and quality of clinical trial training for life sciences organizations developing new medicines for people in need.

The Microsoft awards were announced at the Drug Information Association's 47th annual meeting in Chicago. The awards honor companies using Microsoft solutions to realize business and information technology benefits and revolutionizing medicine by bringing therapeutic breakthroughs to the market faster to fight serious ailments, improve healthcare and enhance people's quality of life.

PPD collaborated with ProtonMedia to develop PPD 3D by integrating ProtonMedia's ProtoSphere, a virtual collaboration environment, with PPD® Adaptive Solutions, an innovative suite of data, technology and performance solutions. PPD 3D empowers PPD clinical research team members to meet remotely with each other and clients and to engage in highly social, interactive and visually appealing 3-D virtual spaces. Users can talk, send instant messages, view and interact with presentation and media content, record notes and access the Web - all at the same time, from anywhere.

"PPD 3D improves the way we train clinical research associates to monitor clinical trials, which is vital for enhancing the quality of site management and clinical monitoring for our clients' research programs," said Mike Wilkinson, Ph.D., executive vice president and chief information officer for PPD. "We are honored that Microsoft, whose technologies are ubiquitous in the life sciences industry, would recognize the results of our collaboration with ProtonMedia, the ideal virtual collaboration technology provider."

Said Ron Burns, CEO of ProtonMedia: "Our joint development with PPD is testament to the power of using Microsoft's technology as the backbone to combine PPD's data and information platform with a virtual collaboration environment like ProtoSphere to deliver a positive impact to the life sciences industry. Our solution shows how life sciences companies can maximize their Microsoft investment, while achieving measureable improvements in their clinical trial training processes and results. We thank Microsoft for recognizing our work with PPD and the value of ProtoSphere in the life sciences industry."

Microsoft award participants consisted of worldwide life sciences corporations in pharmaceutical, biotechnology and medical device companies that are innovatively applying technology to create therapeutic innovations. Winners were selected by a panel of industry experts and will be highlighted on the Microsoft website at and on the Microsoft in Health blog at

"The life sciences industry is uniquely positioned with many new challenges, and pressure is stronger than ever to cut costs and bring new drugs and therapies to market faster," said Michael Naimoli, worldwide managing director, Life Sciences, Microsoft Corp. "Each year, we are impressed with how the winners demonstrate sustainable impacts through technology, and are proud that Microsoft's software platforms play an important role in enabling these achievements in life sciences."

ProtonMedia is the developer of ProtoSphere, the market-leading virtual collaboration environment for the high-performance workplace, and the #1 virtual environment for collaborative PLM in life sciences. ProtoSphere's virtual environment provides an arsenal of business-focused collaboration and communication tools that help companies accelerate decision-making and raise productivity, improving workplace performance overall. The company is a Gartner "Cool Vendor in the High-Performance Workplace" for 2010. Its customers include some of the world's most respected brands. A trial version of ProtoSphere can be downloaded at For more information, visit

Except for historical information, all of the statements, expectations and assumptions, including statements, expectations and assumptions about technologies for clinical trial training, contained in this news release are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based and could cause actual results to differ materially from the forward-looking statements. Other important factors which could cause future results to differ materially include the following: rapid technological advances that make our services less competitive; risks associated with and dependence on strategic relationships; risks associated with acquisitions and investments, such as impairments and integration; the ability to attract, integrate and retain key personnel, including a new CEO; competition in the outsourcing industry; PPD's ability to win new business; overall global economic conditions; economic conditions, research and development spending levels and outsourcing trends in the pharmaceutical, biotechnology and government-sponsored research sectors; consolidation in pharmaceutical and biotechnology industries; loss, delay or modification of large contracts; higher-than-expected cancellation rates; the rate of conversion of backlog into revenue; actual operating performance; risks associated with fixed price contracts and cost overruns; compliance with drug development regulations; and changes in the regulation of the drug development process. These and other PPD risk factors are set forth in more detail from time to time in our SEC filings, copies of which are available free of charge upon request from PPD's investor relations department. PPD assumes no obligation and expressly disclaims any duty to update these forward-looking statements in the future, except as required by applicable law. These forward-looking statements should not be relied upon as representing PPD's estimates or views as of any date subsequent to the date hereof.

Contact Us

Media Contacts:

Randy Buckwalter Senior Manager, Corporate Communications
Tel: +1 919 456 4425

Holly Devine Manager, Corporate Communications
Tel: +1 919 456 6389

Contact Legal Notices Modern Slavery Transparency Statement Privacy Policy

© 2019 Pharmaceutical Product Development, LLC. All rights reserved.